bioAffinity Technologies, Inc. Announces New Clinical Case Study for CyPath® Lung

On March 17, 2026, bioAffinity Technologies, Inc. released a press release detailing a new clinical case study. The study highlights the benefits of their noninvasive test, CyPath® Lung, in the diagnostic pathway for a high-risk patient with multiple pulmonary nodules. The case study demonstrated that CyPath® Lung provided actionable results, helping the patient avoid unnecessary invasive procedures. The test indicated a low likelihood of malignancy, allowing physicians to opt for a follow-up CT scan instead of an immediate lung biopsy. This approach not only reduced patient anxiety but also lowered healthcare costs. The press release also includes information about the CyPath® Lung test's performance in a clinical study, showing high sensitivity, specificity, and accuracy in detecting lung cancer in small nodules. bioAffinity Technologies, Inc. is focused on advancing noninvasive diagnostics for lung cancer and other lung diseases.